142 related articles for article (PubMed ID: 33593235)
1. Direct medical costs of non-alcoholic fatty liver disease in Catalonia at the hospital level: a retrospective multicenter study.
Darbà J
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):341-349. PubMed ID: 33593235
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
[TBL] [Abstract][Full Text] [Related]
3. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
Terai S; Buchanan-Hughes A; Ng A; Lee IH; Hasegawa K
J Gastroenterol; 2021 Mar; 56(3):274-284. PubMed ID: 33496858
[TBL] [Abstract][Full Text] [Related]
4. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.
Romero-Gomez M; Kachru N; Zamorano MA; Darba J; Shreay S
Medicine (Baltimore); 2020 Dec; 99(50):e23506. PubMed ID: 33327291
[TBL] [Abstract][Full Text] [Related]
5. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients.
C Gordon S; Fraysse J; Li S; Ozbay AB; Wong RJ
Am J Gastroenterol; 2020 Apr; 115(4):562-574. PubMed ID: 31833859
[TBL] [Abstract][Full Text] [Related]
6. Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA.
Nguyen AL; Park H; Nguyen P; Sheen E; Kim YA; Nguyen MH
Dig Dis Sci; 2019 Mar; 64(3):698-707. PubMed ID: 30327963
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease.
Cotter TG; Rinella M
Gastroenterology; 2020 May; 158(7):1851-1864. PubMed ID: 32061595
[TBL] [Abstract][Full Text] [Related]
8. Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis.
Tapper EB; Bonafede M; Fishman J; Dodge S; Miller K; Zeng N; Lewandowski D; Bogdanov A
J Med Econ; 2023; 26(1):348-356. PubMed ID: 36866575
[TBL] [Abstract][Full Text] [Related]
9. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
10. Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis.
Darbà J; Marsà A
BMJ Open; 2019 Nov; 9(11):e031271. PubMed ID: 31753879
[TBL] [Abstract][Full Text] [Related]
11. Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls.
Hagström H; Nasr P; Ekstedt M; Hammar U; Widman L; Stål P; Hultcrantz R; Kechagias S; Henriksson M
Clin Gastroenterol Hepatol; 2020 Jun; 18(7):1592-1599.e8. PubMed ID: 31634581
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
13. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
Younossi ZM; Blissett D; Blissett R; Henry L; Stepanova M; Younossi Y; Racila A; Hunt S; Beckerman R
Hepatology; 2016 Nov; 64(5):1577-1586. PubMed ID: 27543837
[TBL] [Abstract][Full Text] [Related]
14. Modern approach to the clinical management of non-alcoholic fatty liver disease.
Del Ben M; Polimeni L; Baratta F; Pastori D; Loffredo L; Angelico F
World J Gastroenterol; 2014 Jul; 20(26):8341-50. PubMed ID: 25024593
[TBL] [Abstract][Full Text] [Related]
15. Economic impact of patients admitted to stroke units in Spain.
Alvarez-Sabín J; Quintana M; Masjuan J; Oliva-Moreno J; Mar J; Gonzalez-Rojas N; Becerra V; Torres C; Yebenes M;
Eur J Health Econ; 2017 May; 18(4):449-458. PubMed ID: 27084749
[TBL] [Abstract][Full Text] [Related]
16. Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease.
Younossi ZM; Zheng L; Stepanova M; Henry L; Venkatesan C; Mishra A
J Clin Gastroenterol; 2015 Mar; 49(3):222-7. PubMed ID: 24637730
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Younossi ZM; Henry L; Bush H; Mishra A
Clin Liver Dis; 2018 Feb; 22(1):1-10. PubMed ID: 29128049
[TBL] [Abstract][Full Text] [Related]
18. Hospital care and medical costs of septic arthritis in Spain: a retrospective multicenter analysis.
Darbà J; Marsà A
J Med Econ; 2022; 25(1):381-385. PubMed ID: 35236216
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system.
Cotter TG; Dong L; Holmen J; Gilroy R; Krong J; Charlton M
J Gastroenterol; 2020 Jul; 55(7):722-730. PubMed ID: 32328797
[TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic fatty liver disease patients attending two metropolitan hospitals in Melbourne, Australia: high risk status and low prevalence.
George ES; Roberts SK; Nicoll AJ; Reddy A; Paris T; Itsiopoulos C; Tierney AC
Intern Med J; 2018 Nov; 48(11):1369-1376. PubMed ID: 29845719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
